Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 20;8(4):2045894018797273. doi: 10.1177/2045894018797273

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Fig. 3. — Time course of changes in ALT, AST, and TBili for the three potential Hy’s law patients. Patient 1539 ALT, Patient 1539 AST, Patient 1539 TBili, Patient 153 ALT, Patient 153 AST, Patient 153 TBili, Patient 583 ALT, Patient 583 AST, Patient 583 TBili. Patient 1539 – randomized to ambrisentan monotherapy. Initiated BCT at day 64 with elevations in AST/TBili at day 142. Patient 583 – randomized to tadalafil monotherapy. Initiated BCT at day 691, with elevations in ALT/AST/TBili at day 901. Patient 153 – randomized to ambrisentan monotherapy. Elevations in ALT/AST/TBili at day 765. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCT, blinded combination therapy; TBili, total bilirubin.

Inline graphic — Time course of changes in ALT, AST, and TBili for the three potential Hy’s law patients. Patient 1539 ALT, Patient 1539 AST, Patient 1539 TBili, Patient 153 ALT, Patient 153 AST, Patient 153 TBili, Patient 583 ALT, Patient 583 AST, Patient 583 TBili. Patient 1539 – randomized to ambrisentan monotherapy. Initiated BCT at day 64 with elevations in AST/TBili at day 142. Patient 583 – randomized to tadalafil monotherapy. Initiated BCT at day 691, with elevations in ALT/AST/TBili at day 901. Patient 153 – randomized to ambrisentan monotherapy. Elevations in ALT/AST/TBili at day 765. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCT, blinded combination therapy; TBili, total bilirubin.